MedDataX Logo

Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS

NCT ID: NCT00486343

Last Updated: 2008-04-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

400 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-07-31

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Asthma is a chronic inflammatory disorder of the airways with a variety of inflammatory processes contributing to the pathogenesis. The inflammation leads to a state of increased airway responsiveness and reversible airway obstruction that causes the recurrent symptoms of asthma. Despite the variety of treatments available for asthma, none are curative, and the disease continues to place a burden on society in terms of morbidity, reduced quality of life (QOL), and ever increasing healthcare costs. The prevalence of asthma continues to increase with current data suggesting that since 1980, adult asthma cases have increased by 75% and in children under 5 years of age the prevalence has increased by 160%.1 Additionally, studies have suggested that the disease severity has been underestimated and that more patients may be classified as having moderate to severe persistent disease.2 Inhaled corticosteroids (ICS) have been the cornerstone of anti-inflammatory treatment for decades and have been shown to improve lung function, decrease symptoms, and reduce asthma exacerbations.3 However, many patients are still inadequately controlled despite treatment according to current asthma management guidelines and have a significant unmet medical need. Such patients are at high risk of serious exacerbations and asthma-related mortality.4 Combining long-acting β2-agonists (LABAs) with low dose ICS has been shown to improve asthma control over using higher doses of ICS alone. However, LABAs act mainly at the bottom of the inflammatory cascade and there are concerns that they may mask underlying inflammation.5 Recently, leukotriene receptor antagonists have been added to ICS as second-line therapy in the management of asthma. Zileuton has been extensively studied in inflammatory diseases such as asthma, in which leukotrienes mediate inflammation.

The aim of this study is to assess the effect of zileuton controlled-release (CR; 1200 mg 2-times daily \[BID\]) on pulmonary function, asthma control, and symptomatic response in adult patients with asthma poorly controlled on moderate dose ICS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Asthma ICS 5-LO Inhibition Leukotrienes Asthma control Asthma exacerbations

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Zileuton CR

Group Type EXPERIMENTAL

Zileuton CR

Intervention Type DRUG

Zileuton CR tablets 2x600mg BID for 24 weeks

2

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo tablets 2x600mg BID for 24 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zileuton CR

Zileuton CR tablets 2x600mg BID for 24 weeks

Intervention Type DRUG

Placebo

Placebo tablets 2x600mg BID for 24 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ZYFLO CR

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female 12-70 years of age (inclusive).
2. Diagnosis of asthma for at least 6 months.
3. Morning FEV1 of 40-80% normal.
4. Demonstrated reversible airflow restriction.
5. Non-smokers.
6. On moderate doses of ICS with inadequate asthma control.
7. Signed ICF

Exclusion Criteria

1. Diagnosis of COPD.
2. Uncontrolled systemic illness.
3. Hypersensitivity to any component of ZYFLO CR
4. Any patient with an unscheduled visit to an ER or hospital for asthma exacerbation within past 3 months.
5. History of hepatitis or active liver disease.
6. ALT greater than 3xULN.
7. History of HIV infection
8. Recent history of drug or alcohol abuse.
9. Oral corticosteroids within one month, cromolyn sodium or nedocromil within 14 days, theophylline, LABA, ZYFLO, or leukotriene modifiers, warfarin or propranolol, inhaled anti-cholinergics, or combination LABA/ICS.
10. Omalizumab within 3 months.
11. Pregnant female.
12. Participation with 30 days in investigational study.
Minimum Eligible Age

12 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Critical Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Critical Therapeutics/Clinquest Inc

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cornelis Wortel, MD, PhD

Role: STUDY_DIRECTOR

Critical Therapeutics/Clinquest Inc

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Critical Therapeutics

Lexington, Massachusetts, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.zyflocr.com

Specific Educational Information on Zileuton CR (Zyflo CR)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CTI-03-C07-401

Identifier Type: -

Identifier Source: org_study_id